CR20200458A - FORMAS CRISTALINAS DE UN ESTIMULANTE DE LA GUANILIL CICLASA SOLUBLE (sGC) - Google Patents

FORMAS CRISTALINAS DE UN ESTIMULANTE DE LA GUANILIL CICLASA SOLUBLE (sGC)

Info

Publication number
CR20200458A
CR20200458A CR20200458A CR20200458A CR20200458A CR 20200458 A CR20200458 A CR 20200458A CR 20200458 A CR20200458 A CR 20200458A CR 20200458 A CR20200458 A CR 20200458A CR 20200458 A CR20200458 A CR 20200458A
Authority
CR
Costa Rica
Prior art keywords
crystalline forms
sgc
soluble
stimulant
guanilyl cyclase
Prior art date
Application number
CR20200458A
Other languages
English (en)
Spanish (es)
Inventor
Kwame W Nti-Addae
Leena Kumari Prasad
Thomas Storz
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65818696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20200458(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of CR20200458A publication Critical patent/CR20200458A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CR20200458A 2018-03-07 2019-03-07 FORMAS CRISTALINAS DE UN ESTIMULANTE DE LA GUANILIL CICLASA SOLUBLE (sGC) CR20200458A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862639846P 2018-03-07 2018-03-07
PCT/US2019/021080 WO2019173551A1 (en) 2018-03-07 2019-03-07 Crystalline forms of an sgc stimulator

Publications (1)

Publication Number Publication Date
CR20200458A true CR20200458A (es) 2020-11-09

Family

ID=65818696

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200458A CR20200458A (es) 2018-03-07 2019-03-07 FORMAS CRISTALINAS DE UN ESTIMULANTE DE LA GUANILIL CICLASA SOLUBLE (sGC)

Country Status (21)

Country Link
US (3) US11466015B2 (OSRAM)
EP (1) EP3762389B1 (OSRAM)
JP (1) JP7423539B2 (OSRAM)
KR (1) KR102782810B1 (OSRAM)
CN (1) CN111836812A (OSRAM)
AU (1) AU2019231724B2 (OSRAM)
BR (1) BR112020018212A2 (OSRAM)
CA (1) CA3092683A1 (OSRAM)
CL (5) CL2020002284A1 (OSRAM)
CO (1) CO2020012493A2 (OSRAM)
CR (1) CR20200458A (OSRAM)
EA (1) EA202092109A1 (OSRAM)
ES (1) ES2980256T3 (OSRAM)
IL (1) IL276853B2 (OSRAM)
MA (1) MA54638A (OSRAM)
MX (5) MX2023004856A (OSRAM)
PE (1) PE20210124A1 (OSRAM)
PH (1) PH12020551394A1 (OSRAM)
SG (1) SG11202008641WA (OSRAM)
TW (1) TWI823903B (OSRAM)
WO (1) WO2019173551A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3092683A1 (en) 2018-03-07 2019-09-12 Cyclerion Therapeutics, Inc. Crystalline forms of an sgc stimulator
JP7542518B2 (ja) * 2018-07-11 2024-08-30 ティセント セラピューティクス インコーポレーテッド ミトコンドリア(mitochonrial)障害の処置のためのsGC刺激剤の使用
WO2021195403A1 (en) * 2020-03-26 2021-09-30 Cyclerion Therapeutics, Inc. Deuterated sgc stimulators
WO2024131860A1 (zh) * 2022-12-21 2024-06-27 广东东阳光药业股份有限公司 氟取代的吲唑化合物的晶型及其用途
AU2023412228A1 (en) * 2022-12-21 2025-07-03 Sunshine Lake Pharma Co., Ltd. Crystal form of fluorine-substituted indazole compound and use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 1−(置換ベンジル)−3−(置換アリール)縮合ピラゾール類、その製造法及びその用途
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
KR100720844B1 (ko) 1998-07-08 2007-05-25 사노피-아벤티스 도이칠란트 게엠베하 황 치환된 설포닐아미노카복실산 n-아릴아미드, 이의 제조방법, 및 이를 함유하는 약제학적 제제
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
CA2698332C (en) 2007-09-06 2012-08-21 Merck Sharp & Dohme Corp. Pyrazole derivatives as soluble guanylate cyclase activators
US7947664B2 (en) 2008-01-24 2011-05-24 Merck Sharp & Dohme Corp. Angiotensin II receptor antagonists
US8741910B2 (en) 2008-11-25 2014-06-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CN102414194A (zh) 2009-02-26 2012-04-11 默沙东公司 可溶性鸟苷酸环化酶激活剂
WO2011119518A1 (en) 2010-03-25 2011-09-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
MA34330B1 (fr) 2010-05-27 2013-06-01 Merck Sharp & Dohme Activateurs de guanylate cyclase soluble
WO2012003405A1 (en) 2010-06-30 2012-01-05 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP2632551B1 (en) 2010-10-28 2016-07-06 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
NZ609955A (en) 2010-11-09 2015-05-29 Ironwood Pharmaceuticals Inc Sgc stimulators
CN104822680B (zh) 2012-11-30 2016-10-12 安斯泰来制药株式会社 咪唑并吡啶化合物
CN105339368B (zh) 2013-06-04 2017-08-15 拜耳制药股份公司 3‑芳基‑取代的咪唑并[1,2‑a]吡啶及其用途
CN104327107A (zh) 2013-10-17 2015-02-04 广东东阳光药业有限公司 一种氟喹诺酮类抗菌药物的制备方法
WO2015187470A1 (en) 2014-06-04 2015-12-10 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
CA2961489A1 (en) 2014-09-17 2016-03-24 Glen Robert RENNIE Sgc stimulators
CN107257796A (zh) 2014-12-02 2017-10-17 拜耳医药股份有限公司 取代的吡唑并[1,5‑a]吡啶和咪唑并[1,2‑a]吡嗪及其用途
EP3872080B1 (en) 2016-09-02 2023-08-16 Cyclerion Therapeutics, Inc. Fused bicyclic sgc stimulators
CA3092683A1 (en) 2018-03-07 2019-09-12 Cyclerion Therapeutics, Inc. Crystalline forms of an sgc stimulator

Also Published As

Publication number Publication date
BR112020018212A2 (pt) 2020-12-29
CA3092683A1 (en) 2019-09-12
JP2021515015A (ja) 2021-06-17
CL2020002284A1 (es) 2020-11-27
TWI823903B (zh) 2023-12-01
WO2019173551A1 (en) 2019-09-12
US11466015B2 (en) 2022-10-11
EA202092109A1 (ru) 2021-03-04
JP7423539B2 (ja) 2024-01-29
US20250115611A1 (en) 2025-04-10
MX2023004858A (es) 2023-11-24
MX2023004857A (es) 2023-11-24
TW201940487A (zh) 2019-10-16
KR102782810B1 (ko) 2025-03-14
CL2021000301A1 (es) 2021-06-18
KR20200128708A (ko) 2020-11-16
PH12020551394A1 (en) 2021-11-22
AU2019231724A1 (en) 2020-10-08
CN111836812A (zh) 2020-10-27
CL2021003531A1 (es) 2022-08-19
US12122782B2 (en) 2024-10-22
PE20210124A1 (es) 2021-01-19
CL2021003536A1 (es) 2022-08-19
MA54638A (fr) 2021-11-10
MX2023004855A (es) 2023-11-24
EP3762389A1 (en) 2021-01-13
WO2019173551A8 (en) 2020-06-11
US20210115050A1 (en) 2021-04-22
AU2019231724B2 (en) 2024-06-27
MX2023004856A (es) 2023-11-24
SG11202008641WA (en) 2020-10-29
CO2020012493A2 (es) 2020-10-30
EP3762389B1 (en) 2024-02-28
IL276853B1 (en) 2026-01-01
IL276853A (en) 2020-10-29
US20230095799A1 (en) 2023-03-30
CL2021003530A1 (es) 2022-08-19
MX2020009183A (es) 2020-10-08
ES2980256T3 (es) 2024-09-30
IL276853B2 (en) 2026-05-01

Similar Documents

Publication Publication Date Title
MX2023004855A (es) Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).
PH12020551843A1 (en) Salts of an fgfr inhibitor
HK1255598A1 (zh) 咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途
PE20181802A1 (es) Derivados de 4-amino-2-(1h-pirazolo[3,4-b]piridin-3-il)-6-oxo-6,7-dihidro-5h-pirrolo[2,3-d]pirimidina y los respectivos (1h-indazol-3-il) derivados como moduladores cgmp para el tratamiento de enfermedades cardiovasculares
MX2020008237A (es) Inhibidores de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol de cgas para tratar enfermedades autoinflamatorias.
PE20120121A1 (es) Derivados de imidazopirazina como inhibidores de syk
MX2021006329A (es) Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmaceuticas y su uso.
ATE424402T1 (de) Imidazopyridinverbindungen
PE20130779A1 (es) Pirimidinas y triazinas condensadas y su uso
BRPI0411825B8 (pt) inibidores de p38 quinase a base de heterociclo de 5 elementos, seus processos de preparação e seus usos, bem como composição farmacêutica
EA201692095A1 (ru) Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака
MY187131A (en) Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
ATE417051T1 (de) Polymorphe von clopidogrel-hydrogensulfat
BRPI0510560A (pt) pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos
WO2004073628A3 (en) Novel compounds
PH12021551180A1 (en) Methods of treating myeloproliferative disorders
JOP20170125A1 (ar) مركبات [8- (فنيل سلفونيل)-3، 8-ديازا ثنائي سيكلو [3. 2. 1] أوكتـ-3-يل] (1h-1، 2، 3-تريازول-4-يل) ميثانون
BR112022024382A2 (pt) Formas sólidas de pralsetinibe
EP4606433A8 (en) FORMULATIONS CONTAINING HETEROCYCLIC PROTEIN KINASE INHIBITORS
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
SI1899350T1 (sl) Derivati pirazolo d azepina kot antagonisti histamina h
MXPA05012082A (es) Compuestos como antagonistas del receptor crf1.
MX2023004924A (es) Nuevo tratamiento de la atrofia muscular espinal (sma).
MX2023008755A (es) Cristales de sal.
SE0100297D0 (sv) New compounds